Chronic kidney disease is a common disease closely related to renal tubular
inflammation and oxidative stress, and no effective treatment is available. Activation of the
nucleotide-binding oligomerization domain-like receptor
protein 3 (NLRP3)
inflammasome is an important factor in renal
inflammation, but the mechanism remains unclear.
Micheliolide (MCL), which is derived from
parthenolide, is a new compound with antioxidative and anti-inflammatory effects and has multiple roles in
tumors and inflammatory diseases. In this study, we investigated the effect of MCL on
lipopolysaccharide- (LPS-) induced
inflammation in renal tubular cells and the related mechanism. We found that MCL significantly suppressed the LPS-induced NF-κB signaling and inflammatory expression of
cytokines, such as
tumor necrosis factor-α and
monocyte chemoattractant protein-1 in a rat renal proximal tubular cell line (NRK-52E). MCL also prevented LPS- and
adenosine triphosphate-induced NLRP3
inflammasome activation in vitro, as evidenced by the inhibition of NLRP3 expression, caspase-1 cleavage, and interleukin-1β and
interleukin-18 maturation and secretion. Additionally, MCL inhibited the reduction of mitochondrial membrane potential and decreases the release of
reactive oxygen species (ROS). Moreover, MCL can prevent NLRP3
inflammasome activation induced by
rotenone, a well-known mitochondrial ROS (mROS) agonist, indicating that the mechanism of MCL's anti-inflammatory effect may be closely related to the mROS. In conclusion, our study indicates that MCL can inhibit LPS-induced renal
inflammation through suppressing the mROS/NF-κB/NLRP3 axis in tubular epithelial cells.